Bank of New York Mellon Corp Raises Stock Holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX)

Bank of New York Mellon Corp lifted its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 18,892.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 698,368 shares of the company's stock after purchasing an additional 694,691 shares during the quarter. Bank of New York Mellon Corp owned 0.29% of BioNTech worth $63,593,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its stake in shares of BioNTech by 39.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 187,355 shares of the company's stock worth $21,349,000 after purchasing an additional 53,319 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of BioNTech during the 4th quarter worth approximately $584,000. GAMMA Investing LLC grew its stake in shares of BioNTech by 5,710.8% during the 1st quarter. GAMMA Investing LLC now owns 53,634 shares of the company's stock worth $4,884,000 after purchasing an additional 52,711 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of BioNTech during the 4th quarter worth approximately $238,000. Finally, LPL Financial LLC grew its stake in shares of BioNTech by 4.9% during the 4th quarter. LPL Financial LLC now owns 38,860 shares of the company's stock worth $4,428,000 after purchasing an additional 1,800 shares during the period. Institutional investors and hedge funds own 15.52% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $138.00 price target on shares of BioNTech in a research note on Wednesday, June 25th. JPMorgan Chase & Co. dropped their price target on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research note on Thursday, May 22nd. Truist Financial reissued a "buy" rating and issued a $155.00 price target (up previously from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. Morgan Stanley set a $133.00 target price on shares of BioNTech and gave the stock an "overweight" rating in a research note on Thursday. Finally, Citigroup reaffirmed a "buy" rating and set a $140.00 target price (down previously from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, BioNTech has an average rating of "Moderate Buy" and an average target price of $137.91.

BioNTech Trading Down 0.9%

Shares of NASDAQ BNTX traded down $1.03 during trading on Friday, hitting $112.89. 521,908 shares of the company were exchanged, compared to its average volume of 943,543. The firm has a market capitalization of $27.14 billion, a PE ratio of -33.20 and a beta of 1.29. BioNTech SE Sponsored ADR has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a fifty day moving average price of $103.56 and a 200-day moving average price of $106.81. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.02 and a current ratio of 10.18.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.